RT Journal Article
SR Electronic
T1 The Presence of Anti-p53 Antibodies in Sera from Patients with Oesophageal Carcinoma: Correlation to Treatment, Tumour Volume and Survival
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 615
OP 620
VO 18
IS 5
A1 STEFAN BERGSTRÖM
A1 MARTIN DREILICH
A1 GUNNAR WAGENIUS
A1 DANIEL BRATTSTRÖM
A1 ANDERS LARSSON
A1 PATRIK HESSELIUS
A1 MICHAEL BERGQVIST
YR 2004
UL http://iv.iiarjournals.org/content/18/5/615.abstract
AB Background: A correlation between mutations in the p53 gene and the presence of anti-p53 antibodies in sera has been reported. The aim of the present study was to analyse anti-p53 antibodies in sera from patients with oesophageal carcinoma and their implications for clinical outcome and survival. Patients and Methods Between 1996 and 2002, patients treated for oesophageal carcinoma at the Department of Oncology, Uppsala University Hospital, Sweden, were asked to donate serum samples during treatment and follow-up. A total of 42 patients, with serum samples collected prior to therapy, were analysed for expressions of anti-p53 antibodies using a commercially available sandwich ELISA (Dianova, Hamburg, Germany). Results: Anti-p53 antibodies did not correlate with investigated laboratory parameters. No correlation between anti-p53 antibodies and tumour volume was found (n=31; r=0.08; p=0.66). Anti-p53 antibodies as a continuous variable was not associated with survival (p=0.42). Neither was the presence of anti-p53 antibodies (according to defined cut-off of 1.1, provided by the manufacturer) associated with survival (p=0.99). Conclusion: The presence of anti-p53 antibodies correlated neither to tumour volume nor to clinical parameters. Copyright © 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved